ITCI Intra-Cellular Therapies Inc.
13.48
+0.46 (+4%)
Previous Close
13.02
Open
13.07
Price To Book
2.09
Market Cap
737710942
Shares
54,726,331
Volume
168,050
Short Ratio
Av. Daily Volume
394,671
NewsSee all news
- Intra-Cellular Therapies to Present at the 8th Annual SVB Leerink Global Healthcare Conference
- Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast
- Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies — What Drives Growth in Today's Competitive Landscape
- Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
- Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares
SEC filingsSee all SEC filings
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594874
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19593238
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19564465
- 8-K - Current report 181239412
- 8-K - Current report 181229998
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Phase 3 interim analysis December 18, 2018 noted trial to stop due to futility.
ITI-007-201
Agitation in patients with dementia
Phase 3 enrollment to be completed 2H 2018.
ITI-007 - Adjunctive Therapy
Bipolar depression
Phase 1/2 top-line presented October 22, 2018.
ITI-214
Parkinson's disease (PD)
Latest News
- Intra-Cellular Therapies to Present at the 8th Annual SVB Leerink Global Healthcare Conference
- Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast
- Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies — What Drives Growth in Today's Competitive Landscape
- Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
- Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI
- Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference
- Is Intra-Cellular Therapies Inc (ITCI) A Good Stock To Buy?
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intra-Cellular Therapies, Inc. (ITCI)
- Intra-Cellular Therapies stock down 22% after discontinuation of Phase 3 trial
- Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer's Disease
- How Should Investors React To Intra-Cellular Therapies, Inc.’s (NASDAQ:ITCI) CEO Pay?
- Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology
- Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia
- Edited Transcript of ITCI earnings conference call or presentation 7-Nov-18 1:30pm GMT
- Does Intra-Cellular Therapies Inc (NASDAQ:ITCI) Have A High Beta?
- Intra-Cellular: 3Q Earnings Snapshot
SEC Filings
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594874
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19593238
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19564465
- 8-K - Current report 181239412
- 8-K - Current report 181229998
- 8-K - Current report 181227787
- 10-Q - Quarterly report [Sections 13 or 15(d)] 181166784
- 8-K - Current report 181164695
- 10-Q - Quarterly report [Sections 13 or 15(d)] 18988563
- 8-K - Current report 18986647